MetaADEDB 2.0 @ LMMD
Erythromycin Ethylsuccinate
(NSYZCCDSJNWWJL-YXOIYICCSA-N)
Structure
SMILES
CCOC(=O)CCC(=O)O[C@H]1[C@@H](O[C@@H](C[C@@H]1N(C)C)C)O[C@@H]1[C@@H](C)[C@H](O[C@@H]2O[C@@H](C)[C@@H]([C@](C2)(C)OC)O)[C@@H](C)C(=O)O[C@H](CC)[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]1(C)O)C)C)O)(C)O
Molecular Formula:
C43H75NO16
Molecular Weight:
862.053
Log P:
2.6798
Hydrogen Bond Acceptor:
17
Hydrogen Bond Donor:
4
TPSA:
226.28
CAS Number(s):
1264-62-6; 41342-53-4
Synonym(s)
1.
Erythromycin Ethylsuccinate
2.
Monomycin
3.
E-Mycin E
4.
EryPed
5.
Erythroped
6.
Eyrthromycin Ethyl Succinate
7.
Pediamycin
8.
Wyamycin E
9.
EMycin E
10.
Ethyl Succinate, Eyrthromycin
11.
Ethylsuccinate, Erythromycin
12.
Succinate, Eyrthromycin Ethyl
External Link(s)
MeSHD015643
PubChem Compound443953
BindingDB96262
ChEBI31555
CHEMBLCHEMBL1200688
DrugCentral1051
KEGGcpd:C12796
dr:D01361
ZINC169356230
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Incorrect product storageFAERS: 9US FAERS
2HypersensitivityFAERS: 6US FAERS
3Product use in unapproved indicationFAERS: 6US FAERS
4VomitingFAERS: 6
Canada Vigilance: 1		Canada Vigilance
US FAERS
5Abdominal PainFAERS: 5
Canada Vigilance: 1		Canada Vigilance
US FAERS
6MalaiseFAERS: 5US FAERS
7NauseaFAERS: 5
Canada Vigilance: 2		Canada Vigilance
US FAERS
8DeafnessFAERS: 4US FAERS
9OtotoxicityFAERS: 4US FAERS
10Product use issueFAERS: 4US FAERS
11Abdominal discomfortFAERS: 3US FAERS
12Drug administration errorFAERS: 3US FAERS
13Drug dispensing errorFAERS: 3US FAERS
14Incorrect dose administeredFAERS: 3US FAERS
15Poor quality drug administeredFAERS: 3US FAERS
16UrticariaFAERS: 3US FAERS
17Back PainFAERS: 2US FAERS
18Drug ineffective for unapproved indicationFAERS: 2US FAERS
19Drug label confusionFAERS: 2US FAERS
20Drug toxicityFAERS: 2US FAERS
21Expired product administeredFAERS: 2US FAERS
22Incorrect drug administration durationFAERS: 2US FAERS
23Incorrect route of drug administrationFAERS: 2US FAERS
24Medication ErrorFAERS: 2US FAERS
25Product preparation errorFAERS: 2US FAERS
26Product quality issueFAERS: 2US FAERS
27Pyloric StenosisFAERS: 2US FAERS
28Wrong technique in product usage processFAERS: 2US FAERS
29AngioedemaFAERS: 1US FAERS
30AnorexiaFAERS: 1US FAERS
31Antigliadin antibody positiveFAERS: 1US FAERS
32ArthralgiaFAERS: 1US FAERS
33Blood glucose increasedFAERS: 1US FAERS
34Burning sensationFAERS: 1US FAERS
35Cardiac ArrestFAERS: 1US FAERS
36Circumstance or information capable of leading to medication errorFAERS: 1US FAERS
37DehydrationFAERS: 1US FAERS
38Documented hypersensitivity to administered productFAERS: 1US FAERS
39Drug effective for unapproved indicationFAERS: 1US FAERS
40Drug ineffectiveFAERS: 1US FAERS
41DyspepsiaFAERS: 1
Canada Vigilance: 1		Canada Vigilance
US FAERS
42DysphemiaFAERS: 1US FAERS
43Expired drug administeredFAERS: 1US FAERS
44FatigueFAERS: 1US FAERS
45GastritisFAERS: 1US FAERS
46General physical health deteriorationFAERS: 1US FAERS
47HepatitisFAERS: 1US FAERS
48HepatomegalyFAERS: 128108177CTD
US FAERS
49Impaired gastric emptyingFAERS: 1US FAERS
50Inappropriate schedule of drug administrationFAERS: 1US FAERS
51InflammationFAERS: 1US FAERS
52Joint swellingFAERS: 1US FAERS
53PalpitationsFAERS: 1US FAERS
54Peripheral swellingFAERS: 1US FAERS
55Product label confusionFAERS: 1US FAERS
56Product physical consistency issueFAERS: 1US FAERS
57Product reconstitution quality issueFAERS: 1US FAERS
58Product substitution issueFAERS: 1US FAERS
59Product taste abnormalFAERS: 1US FAERS
60PruritusFAERS: 1US FAERS
61PurpuraFAERS: 1US FAERS
62RetchingFAERS: 1US FAERS
63Secretion dischargeFAERS: 1US FAERS
64Selective eating disorderFAERS: 1US FAERS
65Serum SicknessFAERS: 1US FAERS
66Therapeutic product effect decreasedFAERS: 1US FAERS
67Urinary tract infectionFAERS: 1US FAERS
68White blood cell count decreasedFAERS: 1US FAERS
69Wrong technique in drug usage processFAERS: 1US FAERS
70Alanine Aminotransferase IncreasedCanada Vigilance: 1Canada Vigilance
71Aspartate Aminotransferase IncreasedCanada Vigilance: 1Canada Vigilance
72Bile Duct Diseases3265170CTD
73Blood alkaline phosphatase increasedCanada Vigilance: 1Canada Vigilance
74Liver neoplasms25058030CTD
75PainCanada Vigilance: 1Canada Vigilance
76jaundiceCanada Vigilance: 1Canada Vigilance
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.